Defendant Name: Northwest Biotherapeutics, Inc.

Defendant Type: Public Company
SIC Code: 2834
CUSIP: 66737P60

Initial Case Details

Legal Case Name In the Matter of Northwest Biotherapeutics, Inc.
First Document Date 10-Oct-2019
Initial Filing Format Administrative Action
File Number 3-19582
Allegation Type Issuer Reporting and Disclosure
AAER 4099

Violations Alleged

Exchange Act
Rule 13a-15
Sec 13(b)(2)(B)


First Resolution Date 10-Oct-2019
Headline Total Penalty and Disgorgement

See Related Documents

Related Documents:

34-87281 10-Oct-2019 Administrative Proceeding
Order Instituting Cease-and-Desist Proceedings, Pursuant to Section 21C of the Securities Exchange Act of 1934, Making Findings, and Imposing and Cease-and-Desist Order
On October 10, 2019, the SEC instituted settled cease-and-desist proceedings against Northwest Biotherapeutics, Inc. ("Respondent"). The SEC stated: "These proceedings involve violations of the federal securities laws in connection with the Respondent's Internal Control over Financial Reporting ("ICFR"). Respondent failed to create and implement effective ICFR for twelve consecutive annual reporting periods from 2007 through 2018."
34-87281-s 10-Oct-2019 Administrative Summary
SEC Files Settled Action Against Biotechnology Company Related to Unremediated Material Weaknesses Spanning Twelve Years
The SEC stated that: "[It] filed a settled action against Northwest Biotherapeutics (NWBO) for failing to maintain internal control over financial reporting (ICFR) for twelve consecutive annual reporting periods. In each of its annual Form 10-K filings with the Commission over more than a decade, NWBO disclosed material weaknesses, many of which recurred year after year, with insufficient effort at remediation."